NASDAQ:BCDA BioCardia (BCDA) Stock Price, News & Analysis $2.27 -0.23 (-9.20%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$2.15▼$2.4850-Day Range$2.20▼$4.0252-Week Range$1.96▼$23.25Volume275,554 shsAverage Volume348,372 shsMarket Capitalization$4.13 millionP/E RatioN/ADividend YieldN/APrice Target$25.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get BioCardia alerts: Email Address BioCardia MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,001.3% Upside$25.00 Price TargetShort InterestHealthy4.33% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$8,278 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($5.06) to ($1.27) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.20 out of 5 stars 3.5 Analyst's Opinion Consensus RatingBioCardia has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageBioCardia has only been the subject of 1 research reports in the past 90 days.Read more about BioCardia's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.33% of the float of BioCardia has been sold short.Short Interest Ratio / Days to CoverBioCardia has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioCardia has recently increased by 104.09%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioCardia does not currently pay a dividend.Dividend GrowthBioCardia does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BCDA. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for BioCardia this week, compared to 1 article on an average week.Search Interest10 people have searched for BCDA on MarketBeat in the last 30 days. MarketBeat Follows5 people have added BioCardia to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioCardia insiders have bought more of their company's stock than they have sold. Specifically, they have bought $8,278.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders20.00% of the stock of BioCardia is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 20.57% of the stock of BioCardia is held by institutions.Read more about BioCardia's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioCardia are expected to grow in the coming year, from ($5.06) to ($1.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioCardia is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioCardia is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about BioCardia's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying with both fists. They know it's only a matter of time before another bull run. Now, Crypto Insiders Are Scooping up Lesser-Known Coins and Making Serious BankGo here to get full details on this crypto now. About BioCardia Stock (NASDAQ:BCDA)BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its leading product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. BioCardia, Inc. is based in Sunnyvale, California.Read More BCDA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BCDA Stock News HeadlinesAugust 31, 2024 | stockhouse.comBioCardia Announces FDA Market Clearance of Morph® DNA(TM) Steerable Introducer Product FamilyAugust 30, 2024 | benzinga.comWhat In The World Is Going On With UTime (WTO) Stock Today?September 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 30, 2024 | msn.comEnsysce Biosciences (ENSC) Stock Is Down 30% Today: What's Going On?August 30, 2024 | msn.comWhy BioCardia (BCDA) Stock Is Falling TodayAugust 30, 2024 | marketwatch.comBioCardia Shares Drop 10% After Public Offering PricesAugust 30, 2024 | tmcnet.comBioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq RulesAugust 29, 2024 | finanznachrichten.deBioCardia, Inc.: BioCardia Announces FDA Market Clearance of Morph DNA Steerable Introducer Product FamilySeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 29, 2024 | msn.comWhy BioCardia (BCDA) Stock Is Up 95% TodayAugust 29, 2024 | globenewswire.comBioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product FamilyAugust 29, 2024 | marketwatch.comStock Market Today: Dow futures rise as Nvidia results drive rotation from megacap techAugust 21, 2024 | finanznachrichten.deBioCardia, Inc.: FDA Approves CardiAMP Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define TreatmentAugust 21, 2024 | globenewswire.comFDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define TreatmentAugust 17, 2024 | ca.finance.yahoo.comTAL Aug 2024 13.000 callAugust 17, 2024 | ca.finance.yahoo.comTAL Aug 2024 11.000 putAugust 17, 2024 | ca.finance.yahoo.comTAL Aug 2024 8.000 putAugust 16, 2024 | finance.yahoo.comMercer Global Listed Infras A12H0.2700€ (0P0001L5K4.F)See More Headlines Receive BCDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioCardia and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/07/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BCDA CUSIPN/A CIK925741 Webwww.biocardia.com Phone(650) 226-0120Fax310-861-5299Employees40Year FoundedN/APrice Target and Rating Average Stock Price Target$25.00 High Stock Price Target$25.00 Low Stock Price Target$25.00 Potential Upside/Downside+1,001.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($7.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,570,000.00 Net Margins-1,999.77% Pretax Margin-1,999.77% Return on Equity-3,638.68% Return on Assets-278.27% Debt Debt-to-Equity RatioN/A Current Ratio0.39 Quick Ratio0.39 Sales & Book Value Annual Sales$428,000.00 Price / Sales9.66 Cash FlowN/A Price / Cash FlowN/A Book Value($0.92) per share Price / Book-2.47Miscellaneous Outstanding Shares1,821,000Free Float1,457,000Market Cap$4.13 million OptionableOptionable Beta1.25 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesDr. Peter A. Altman Ph.D. (Age 57)CEO, President & Director Comp: $515.51kMr. David McClung (Age 61)Chief Financial Officer Comp: $370.86kMr. Edward M. Gillis (Age 62)Senior Vice President of Devices Comp: $263.1kKey CompetitorsAptorum GroupNASDAQ:APMiBioNYSE:IBIOGalmed PharmaceuticalsNASDAQ:GLMDTurnstone BiologicsNASDAQ:TSBXExicureNASDAQ:XCURView All CompetitorsInsidersPeter AltmanBought 300 shares on 7/1/2024Total: $915.00 ($3.05/share)Peter AltmanBought 200 shares on 6/28/2024Total: $598.00 ($2.99/share)Peter AltmanBought 500 shares on 6/21/2024Total: $1,645.00 ($3.29/share)Peter AltmanBought 500 shares on 6/14/2024Total: $1,760.00 ($3.52/share)Peter AltmanBought 1,000 shares on 6/10/2024Total: $3,360.00 ($3.36/share)View All Insider Transactions BCDA Stock Analysis - Frequently Asked Questions How have BCDA shares performed this year? BioCardia's stock was trading at $9.9630 on January 1st, 2024. Since then, BCDA shares have decreased by 77.2% and is now trading at $2.27. View the best growth stocks for 2024 here. How were BioCardia's earnings last quarter? BioCardia, Inc. (NASDAQ:BCDA) issued its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by $0.78. BioCardia had a negative net margin of 1,999.77% and a negative trailing twelve-month return on equity of 3,638.68%. When did BioCardia's stock split? BioCardia shares reverse split before market open on Thursday, May 30th 2024. The 1-15 reverse split was announced on Thursday, May 30th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did BioCardia IPO? BioCardia (BCDA) raised $51 million in an initial public offering (IPO) on the week of July 20th 2015. The company issued 3,900,000 shares at a price of $12.00-$14.00 per share. Cantor Fitzgerald & Co. served as the underwriter for the IPO and Roth Capital Partners and Maxim Group were co-managers. How do I buy shares of BioCardia? Shares of BCDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of BioCardia own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioCardia investors own include Arotech (ARTX), CytoDyn (CYDY), China Gold International Resources (CGG), BioSolar (BSRC), Blink Charging (BLNK) and Aurcana Silver (AUNFF). This page (NASDAQ:BCDA) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCardia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCardia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
